Hyperuricemia Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arthrosi Therapeutics, Shanton Pharma Pte. Ltd., Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Sheny

Hyperuricemia Pipeline constitutes 10+ key companies continuously working towards developing 12+ Hyperuricemia treatment therapies, analyzes DelveInsight.

Hyperuricemia Overview:

Hyperuricemia refers to elevated levels of uric acid in the blood-typically above 6 mg/dL in women and 7 mg/dL in men-and affects around 38 million people in the United States. Its global prevalence is rising, largely due to the increasing adoption of Western dietary and lifestyle habits. Although many individuals with hyperuricemia experience no symptoms, the condition can lead to gout and kidney stones. It stems from either excessive production or insufficient excretion of uric acid and is often associated with high cellular turnover, kidney dysfunction, and various metabolic conditions. Furthermore, hyperuricemia is linked to a higher risk of cardiovascular disease, obesity, high blood pressure, and chronic kidney disease.

The imbalance between uric acid generation and elimination typically drives hyperuricemia. Uric acid is a byproduct of purine metabolism and is mainly cleared by the kidneys. However, impaired kidney function-due to decreased glomerular filtration, reduced tubular secretion, or increased reabsorption-often leads to its accumulation. About two-thirds of uric acid is excreted via the kidneys, while the rest is removed through the gastrointestinal tract. Factors such as diets rich in purines, rapid cell breakdown (as seen in conditions like rhabdomyolysis or hemolysis), and certain medications can elevate uric acid production.

Request for a detailed insights report on Hyperuricemia pipeline insights @ https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Hyperuricemia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hyperuricemia Therapeutics Market.

Key Takeaways from the Hyperuricemia Pipeline Report

DelveInsight's Hyperuricemia pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Hyperuricemia treatment.
Takeda's gout medication, Uloric (febuxostat), has been officially discontinued in the U.S. The FDA flagged it in their drug shortage database following accumulating cardiovascular safety concerns and a black‐box warning issued in 2019. The drug will remain available to wholesalers only through March 31, 2026 to allow for patient transitions.
In March 2025, they submitted a Type B meeting package to the FDA and awaited feedback by April 26th to finalize steps toward NDA submission via a 505(b)(2) pathway
Key Hyperuricemia companies such as Arthrosi Therapeutics, Shanton Pharma Pte. Ltd., Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Shenyang Sunshine Pharmaceutical Co., LTD., Intelligem Therapeutics Australia Pty Ltd, and others are evaluating new drugs for Hyperuricemia to improve the treatment landscape.
Promising Hyperuricemia pipeline therapies in various stages of development include AR882, ABP-671, SAP-001, and others.

Hyperuricemia Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Hyperuricemia Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hyperuricemia treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hyperuricemia market.

Download our free sample page report on Hyperuricemia pipeline insights https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hyperuricemia Emerging Drugs

AR882: Arthrosi Therapeutics

AR882 is an innovative drug candidate developed to address hyperuricemia, particularly in patients with gout. It acts as a highly selective and potent inhibitor of Uric Acid Transporter 1 (URAT1), a key protein involved in the kidney's reabsorption of uric acid. By inhibiting URAT1, AR882 promotes the elimination of uric acid through urine, effectively lowering its concentration in the bloodstream. This targeted approach may help reduce complications linked to hyperuricemia, including gout flares and tophi formation. AR882 is currently undergoing Phase III clinical trials for the treatment of hyperuricemia.

ABP-671: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.

ABP-671 is a URAT1 (Urate Transporter 1) inhibitor that targets the kidney's reabsorption of uric acid. As a once-daily oral monotherapy, it works by decreasing uric acid reabsorption and enhancing its urinary excretion, leading to a reduction in serum uric acid (sUA) levels. Over time, this can shrink and prevent the formation of tophi, helping to reduce the frequency of gout attacks. By maintaining healthy sUA levels, ABP-671 may also lower the risk of complications related to hyperuricemia, such as diabetes, cardiovascular issues, and kidney disease. In a recent clinical trial, the drug successfully met key sUA targets, with about 93% and 77% of participants achieving sUA levels below 6 mg/dL and 5 mg/dL, respectively. ABP-671 is currently in Phase III of clinical development for hyperuricemia treatment.

Hyperuricemia Companies

Around 10 or more major companies are actively developing therapies for hyperuricemia. Among them, Arthrosi Therapeutics has a drug candidate in the most advanced stage of development-Phase III.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Hyperuricemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Hyperuricemia Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Hyperuricemia Therapies and Key Companies: Hyperuricemia Clinical Trials and advancements https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hyperuricemia Pipeline Therapeutic Assessment
• Hyperuricemia Assessment by Product Type
• Hyperuricemia By Stage
• Hyperuricemia Assessment by Route of Administration
• Hyperuricemia Assessment by Molecule Type

Download Hyperuricemia Sample report to know in detail about the Hyperuricemia treatment market @ Hyperuricemia Therapeutic Assessment https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Hyperuricemia Current Treatment Patterns
4. Hyperuricemia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hyperuricemia Late-Stage Products (Phase-III)
7. Hyperuricemia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hyperuricemia Discontinued Products
13. Hyperuricemia Product Profiles
14. Hyperuricemia Key Companies
15. Hyperuricemia Key Products
16. Dormant and Discontinued Products
17. Hyperuricemia Unmet Needs
18. Hyperuricemia Future Perspectives
19. Hyperuricemia Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Hyperuricemia Pipeline Reports Offerings https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.